STEAP4 Antibody

What is STEAP4 and why is it important for research?

STEAP4 (Six-Transmembrane Epithelial Antigen of Prostate 4, also known as STAMP2, TIARP, or TNFAIP9) is a 459-amino acid metalloreductase that functions as a NADPH-dependent ferric-chelate reductase. It mediates sequential transmembrane electron transfer from NADPH to FAD and onto heme, ultimately reducing Fe(3+) to Fe(2+) and Cu(2+) to Cu(1+) . STEAP4 plays critical roles in:

• Iron and copper homeostasis

• Inflammatory responses

• Metabolic regulation

• Adipocyte function and development

• Cancer progression (particularly in prostate and breast cancers)

Its dysregulation has been implicated in obesity, insulin resistance, and inflammatory conditions, making it a significant target for research across multiple fields .

What tissue types express STEAP4?

STEAP4 expression varies across tissues, with differential expression patterns making it important to select appropriate experimental models:

The ubiquitous but differential expression patterns necessitate careful experimental design when studying STEAP4 in specific contexts .

What are the common applications for STEAP4 antibodies?

STEAP4 antibodies can be utilized in multiple experimental approaches:

The optimal dilution should be determined experimentally for each antibody and application .

How should STEAP4 antibodies be stored and handled?

For optimal performance and longevity of STEAP4 antibodies:

• Store at -20°C in aliquots to minimize freeze-thaw cycles

• Most commercial STEAP4 antibodies are provided in PBS with 0.02% sodium azide and 50% glycerol, pH 7.3

• Small aliquots (≤20 μL) typically contain 0.1% BSA as a stabilizer

• For long-term storage (>1 year), maintain antibodies at -80°C

• Allow antibodies to equilibrate to room temperature before opening

• Centrifuge briefly before use to collect material at the bottom of the tube

Following these guidelines will help maintain antibody integrity and experimental reproducibility .

How can I address cross-reactivity concerns when using STEAP4 antibodies?

Cross-reactivity with other STEAP family members is a legitimate concern given their structural similarities. To ensure specificity:

• Negative controls: Include tissues/cells with confirmed low STEAP4 expression

• Positive controls: Use tissues with known high expression (adipose tissue, prostate)

• Validation using multiple antibodies: Use antibodies targeting different epitopes of STEAP4

• Knockout/knockdown validation: Compare antibody reactivity in STEAP4-depleted samples

• Pre-absorption test: Pre-incubate antibody with immunizing peptide to confirm epitope specificity

Research indicates that carefully purified STEAP4 antibodies, such as those affinity-purified from monospecific antiserum by immunoaffinity chromatography, show minimal cross-reactivity with other STEAP proteins . For absolute confirmation of specificity, consider using CRISPR-Cas9 knockout cell lines as definitive negative controls.

What are the methodological considerations for detecting STEAP4 in different subcellular compartments?

STEAP4 exhibits complex subcellular localization patterns that require specific methodological approaches:

STEAP4 almost completely colocalizes with transferrin and transferrin receptor 1 in the Golgi complex and plasma membrane . For optimal visualization, use cells with high endogenous STEAP4 expression (adipocytes, prostate cells) or controlled exogenous expression systems .

What methodologies are effective for studying STEAP4's role in tumor progression?

Based on emerging research linking STEAP4 to cancer progression, particularly in breast, prostate, and oral cancers, several methodological approaches are recommended:

• Tissue microarray (TMA) analysis: STEAP4 immunohistochemical staining of cancer tissues and correlation with clinicopathological parameters

  • Use scoring systems based on staining intensity (0-3) and percentage of positive cells (0-4)

  • Categorize patients into low and high expression groups based on total score results

• Functional studies:

  • siRNA-mediated knockdown of STEAP4 to assess effects on cell proliferation, migration, invasion

  • STEAP4 overexpression experiments to confirm oncogenic properties

  • Combination therapies (e.g., iron chelators + HER2 inhibitors in breast cancer)

• Mechanistic investigations:

  • RNA-seq to identify STEAP4-regulated genes (e.g., NOTCH4 in prostate cancer)

  • Co-immunoprecipitation to identify protein interaction partners

  • Iron/copper metabolism assays to link metalloreductase activity to cancer phenotypes

How can I optimize antigen retrieval for STEAP4 immunohistochemistry?

Effective antigen retrieval is crucial for successful STEAP4 IHC staining:

• EDTA-based retrieval (preferred method):

  • Use 1 mM EDTA buffer, pH 9.0

  • Heat in pressure cooker for 3 minutes after reaching full pressure

  • Allow slides to cool in retrieval solution for 20-30 minutes

• Citrate-based retrieval (alternative method):

  • Use 10 mM citrate buffer, pH 6.0

  • Heat in microwave or water bath at 95-98°C for 20 minutes

  • Cool slowly to room temperature

• Enzymatic retrieval (for difficult samples):

  • Proteinase K (20 μg/mL) for 10-15 minutes at 37°C

  • Monitor carefully to prevent over-digestion

Research indicates that EDTA-based retrieval at higher pH (9.0) generally yields better results for STEAP4 detection in formalin-fixed paraffin-embedded tissues, with stronger and more specific staining patterns .

What are the best approaches for quantifying STEAP4 expression changes in response to inflammatory stimuli?

Given STEAP4's responsiveness to inflammatory signals, precise quantification methods are essential:

• RT-qPCR for transcriptional changes:

  • Design primers spanning exon junctions to avoid genomic DNA amplification

  • Use multiple reference genes (GAPDH, β-actin, and 18S rRNA) for accurate normalization

  • Employ the 2^(-ΔΔCt) method for relative quantification

• Western blot for protein-level changes:

  • Use appropriate loading controls (β-actin for whole cell lysates, Na+/K+ ATPase for membrane fractions)

  • Employ densitometry with linear dynamic range validation

  • Consider multiplexed detection systems for simultaneous analysis of multiple proteins

• Flow cytometry for single-cell analysis:

  • Use fluorophore-conjugated antibodies (e.g., Alexa Fluor 488-conjugated anti-STEAP4)

  • Include appropriate isotype controls

  • Analyze median fluorescence intensity rather than percentage of positive cells

• ELISA for secreted forms or quantitative analysis:

  • Develop sandwich ELISA using antibodies targeting different epitopes

  • Include standard curves using recombinant STEAP4 protein

Studies show that STEAP4 expression is markedly upregulated by TNF-α in adipocytes and by IL-6 in hepatocytes, making these experimental systems valuable for studying inflammatory regulation .

Why might I observe multiple bands when using STEAP4 antibodies in Western blotting?

Multiple bands in STEAP4 Western blots may arise from several sources:

For optimal detection of the expected 52 kDa band, use fresh samples with complete protease inhibitor cocktails and ensure thorough denaturation of samples .

How can I optimize immunoprecipitation protocols for STEAP4?

Successful STEAP4 immunoprecipitation requires considerations for its transmembrane nature:

• Lysis buffer optimization:

  • Use buffers containing 1% NP-40 or Triton X-100 for mild extraction

  • For more stringent extraction, include 0.1% SDS or 0.5% sodium deoxycholate

  • Include protease inhibitors, phosphatase inhibitors, and EDTA

• Antibody selection and amount:

  • Use 0.5-4.0 μg antibody per 1-3 mg of total protein lysate

  • Select antibodies validated for IP applications

• Pre-clearing strategy:

  • Pre-clear lysates with protein A/G beads to reduce non-specific binding

  • Use species-matched normal IgG as negative control

• Washing conditions:

  • Perform at least 4-5 washes with decreasing detergent concentrations

  • Final wash with detergent-free buffer to remove residual detergents

• Elution methods:

  • Gentle elution: non-reducing sample buffer at room temperature

  • Standard elution: reducing sample buffer with heating at 70°C (not 100°C)

Studies indicate that incorporating brief sonication (3 cycles of 10 seconds each) during lysis improves STEAP4 extraction from membrane compartments .

What approaches can resolve inconsistent STEAP4 staining in immunohistochemistry?

Inconsistent IHC staining is a common challenge that can be addressed systematically:

• Fixation optimization:

  • Use 10% neutral buffered formalin for 24-48 hours

  • Avoid over-fixation which can mask STEAP4 epitopes

  • For frozen sections, use acetone fixation for 10 minutes at -20°C

• Blocking improvements:

  • Use 5% goat serum with 0.1% Triton X-100 in PBS for 1 hour

  • Consider adding 1% BSA to reduce background

  • For highly autofluorescent tissues, include 0.1-0.3% Sudan Black B

• Signal amplification:

  • Employ polymer-based detection systems for enhanced sensitivity

  • Consider tyramide signal amplification for low abundance detection

  • Use appropriate HRP substrates (DAB works well for STEAP4)

• Antibody validation:

  • Test multiple antibodies targeting different epitopes

  • Include positive control tissues (prostate, adipose tissue)

  • Use STEAP4 knockout tissues as negative controls

• Technical standardization:

  • Maintain consistent incubation times and temperatures

  • Use humidity chambers to prevent section drying

  • Prepare fresh working solutions of antibodies

Research suggests that for difficult samples, a double antigen retrieval approach (combining heat-induced and enzymatic methods) may improve STEAP4 detection .

How can STEAP4 antibodies be used to investigate its role in adipocyte metabolism?

STEAP4 plays crucial roles in adipocyte development and metabolism, particularly in inflammatory conditions:

• Differentiation studies:

  • Track STEAP4 expression during adipocyte differentiation using Western blot and IF

  • Compare expression between preadipocytes and mature adipocytes

  • Correlate STEAP4 levels with adipogenic markers (PPARγ, C/EBPα)

• Functional analyses:

  • Assess effects of STEAP4 antibody treatment on:

    • Pre-adipocyte proliferation (Trypan Blue exclusion, CCK-8 assays)

    • Apoptosis (annexin V-FITC labeling, caspase-3/8 activity)

    • Adipogenesis (Oil Red O staining)

    • Insulin-stimulated glucose uptake (2-deoxy-d-[3H]-glucose uptake)

• Inflammatory response:

  • Examine STEAP4 regulation by inflammatory cytokines (TNF-α, IL-6)

  • Analyze STEAP4-dependent inflammatory signaling pathways

  • Assess impact of STEAP4 modulation on macrophage polarization

Studies have demonstrated that STEAP4 antibody treatment inhibits pre-adipocyte proliferation, promotes apoptosis, and induces insulin-stimulated glucose uptake in mature human adipocytes, suggesting complex roles in adipocyte biology .

What are the best methodological approaches for investigating STEAP4's role in cancer?

The emerging significance of STEAP4 in cancer necessitates robust methodological approaches:

• Expression profiling:

  • Compare STEAP4 levels in matched tumor/normal tissues using IHC and WB

  • Correlate expression with clinicopathological parameters and survival outcomes

  • Analyze subcellular localization patterns in different cancer types

• Functional characterization:

  • Perform knockdown/overexpression experiments to assess:

    • Cell proliferation (colony formation, MTT/CCK-8 assays)

    • Migration/invasion (Transwell, wound healing assays)

    • Anchorage-independent growth (soft agar assays)

    • Tumor growth in xenograft models

• Mechanism investigation:

  • Study STEAP4's iron reductase activity in cancer cells

  • Assess combined inhibition of STEAP4 and HER2 pathways in breast cancer

  • Explore STEAP4-NOTCH4 regulatory axis in prostate cancer

• Therapeutic targeting:

  • Test iron chelators (e.g., Deferiprone) in combination with cancer-specific drugs

  • Evaluate STEAP4 antibodies for potential therapeutic applications

  • Develop small molecule inhibitors targeting STEAP4's metalloreductase activity

Recent research has identified STEAP4 as a novel breast cancer biomarker, particularly in HER2+ subtypes, and has demonstrated that blocking STEAP4 pathways can significantly reduce cancer cell growth in vitro .

How can STEAP4 antibodies be utilized to investigate its structure-function relationships?

Understanding STEAP4's complex domain organization and function requires specialized approaches:

• Domain-specific antibodies:

  • Use antibodies targeting different domains:

    • N-terminal cytoplasmic domain (oxidoreductase activity)

    • Transmembrane domains (channel function)

    • C-terminal region (potential regulatory functions)

• Structural studies:

  • Employ antibodies for immunoprecipitation followed by mass spectrometry

  • Use proximity labeling with antibody-enzyme conjugates

  • Perform limited proteolysis with antibody protection

• Functional mapping:

  • Correlate antibody binding to specific domains with functional outcomes

  • Use domain-blocking antibodies to isolate functional contributions

  • Combine with mutagenesis approaches for comprehensive mapping

• Heterotrimeric complex analysis:

  • Investigate STEAP homo-trimers and hetero-trimers using co-IP

  • Assess antibody binding to different oligomeric states

  • Study conformational changes using antibody accessibility

Cryo-electron microscopy has revealed that STEAP4 forms domain-swapped trimeric structures that orient NADPH, FAD, and heme to enable electron transfer across membranes, providing insights into its metalloreductase function .

What techniques can be used to study STEAP4's interactions with iron and copper in cellular contexts?

Investigating STEAP4's metalloreductase activities requires specialized methodological approaches:

• Metal reduction assays:

  • Measure Fe(3+) reduction using colorimetric ferrozine assay

  • Assess Cu(2+) reduction with bathocuproine disulfonate

  • Perform assays with purified protein or in cellular contexts

• Metal uptake studies:

  • Use radioactive isotopes (55Fe, 64Cu) to track metal uptake

  • Employ fluorescent metal sensors for real-time visualization

  • Combine with STEAP4 modulation (knockdown/overexpression)

• Localization of metal-protein interactions:

  • Utilize antibodies in combination with metal-specific probes

  • Perform transmission electron microscopy with immunogold labeling

  • Apply X-ray fluorescence microscopy for elemental mapping

• Functional consequences:

  • Assess impact of iron/copper loading on STEAP4 expression

  • Measure oxidative stress parameters in relation to STEAP4 activity

  • Investigate metabolic outcomes of STEAP4-mediated metal reduction

Research shows that STEAP4 binds Fe(3+)-NTA within a positively charged ring, indicating that iron gets reduced while in complex with its chelator, which has implications for understanding metal uptake mechanisms in cells .

How can researchers effectively combine STEAP4 antibodies with genetic manipulation approaches?

Integrating antibody-based detection with genetic modulation provides powerful insights:

• Knockdown validation strategies:

  • Verify siRNA/shRNA efficiency using Western blot with STEAP4 antibodies

  • Confirm specificity by rescuing knockdown phenotypes with expression constructs

  • Use antibodies to screen CRISPR-Cas9 knockout clones

• Overexpression systems:

  • Tag STEAP4 constructs (FLAG, HA, GFP) and verify expression with both tag and STEAP4 antibodies

  • Assess localization of overexpressed protein relative to endogenous STEAP4

  • Compare functional outcomes between tagged and untagged systems

• Domain mapping:

  • Create truncation/deletion mutants and analyze using domain-specific antibodies

  • Employ site-directed mutagenesis to identify critical residues

  • Correlate structural changes with functional outcomes

• In vivo applications:

  • Generate conditional knockout mouse models and validate tissue-specific deletion

  • Use antibodies to assess compensatory changes in other STEAP family members

  • Combine with tissue-specific promoters for controlled expression